首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1622091

2024 年至 2031 年過敏免疫療法市場（按過敏原類型、年齡層、免疫療法類型、通路和地區劃分）

Allergy Immunotherapy Market By Allergen Type, By Age Group, By Type Of Immunotherapy (Subcutaneous Immunotherapy, Sublingual Immunotherapy ), By Distribution Channel, & Region For 2024-2031

出版日期: 2024年11月25日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

過敏免疫療法市場評估 - 2024-2031

2023 年過敏免疫治療市場規模價值 20.8 億美元，預計到 2031 年將成長 38.7 億美元，預測期內複合年增長率為 8.10%。由於過敏性鼻炎、氣喘、食物過敏等過敏性疾病的發生率不斷上升，過敏免疫治療市場正在不斷擴大。隨著越來越多的人尋求有效的長期治療方法，免疫療法優於標準藥物的趨勢明顯。對於希望緩解症狀但又不想持續使用抗組織胺或皮質類固醇的人來說尤其如此。

此外，過敏原特異性免疫治療產品和給藥方法（包括舌下片和注射）的進步正在提高患者的治療可及性和依從性。人們對免疫療法益處的認識不斷提高以及醫療專業人士的推薦正在推動市場擴張。隨著對個人化醫療的日益重視，過敏免疫治療產業預計在未來幾年將大幅成長。

過敏免疫療法市場定義/概述

過敏免疫療法是一種旨在降低對過敏原的敏感性並長期緩解過敏症狀的治療方法。特定的過敏原透過皮下給藥（過敏原免疫療法）或以舌下片或靜脈注射的形式逐漸增加劑量。這種機制使免疫系統對過敏原產生耐受性，從而減輕過敏反應的嚴重程度。

它透過逐漸降低免疫系統對某些過敏原的敏感性來治療過敏性疾病。透過注射（皮下免疫療法）或舌下片引入控制量的過敏原。這種方法可以隨著時間的推移減輕過敏反應的嚴重程度，並在治療結束後提供長期緩解。過敏免疫療法有利於治療過敏性鼻炎、氣喘和某些食物過敏等疾病，改善患者的生活品質並減少藥物使用。

過敏免疫療法的未來很可能圍繞著個人化治療技術展開，該技術利用基因和生物標記數據為特定患者定製藥物。微針和穿戴式裝置等創新的藥物輸送系統可望提高患者的依從性和舒適度。此外，對新的過敏原來源和藥物組合的研究可能會擴大治療選擇。

醫療專業人員和患者的意識不斷提高如何影響過敏免疫治療市場的成長？

醫療專業人士和患者的意識不斷提高，推動了過敏免疫治療市場的成長。越來越多的醫療保健專業人士認識到免疫療法相對於傳統過敏藥物的長期益處，並正在推廣免疫療法作為可行的過敏治療選擇。隨著人們對免疫療法的有效性和安全性的認知度不斷提高，臨床實踐也發生了變化，皮下免疫療法(SCIT) 和舌下免疫療法(SLIT) 等療法的接受度也不斷提高。促進了市場的成長。

從患者的角度來看，人們越來越認識到過敏免疫療法能夠提供長期的舒適感，而不僅僅是暫時緩解症狀，這促使對這些療法的需求增加。患者越來越瞭解自己的選擇，並且更有可能選擇個人化的長期過敏治療。這種不斷增長的需求，加上醫療保健專業人士的建議，正在推動免疫療法的採用並擴大整個市場。

高昂的治療費用是否限制了過敏免疫治療市場的發展？

治療費用高是過敏免疫治療市場的一個主要障礙，限制了患者接受治療的機會。過敏免疫治療，尤其是皮下免疫治療（SCIT），需要數年多次治療，導致患者的治療費用高。在許多地區，此類治療的保險覆蓋範圍可能有限或不存在，需要患者支付現金。儘管這種治療方法可以長期緩解慢性過敏問題，但許多人因其高昂的費用而卻步。

此外，免疫療法的前期和經常性成本較高，限制了其應用，特別是在低收入地區和醫療資源不足的國家。對於資金緊張的醫療保健系統來說，為大規模免疫療法計畫分配資源可能並不實際，這進一步限制了市場擴張。因此，過敏的盛行率不斷上升，儘管免疫療法的療效已得到證實，但成本仍然是廣泛使用這些治療方法的重大障礙。

Allergy Immunotherapy Market size was valued at USD 2.08 Billion in 2023 and is projected to grow USD 3.87 Billion by 2031, exhibiting a CAGR of 8.10% during the forecast period. The Allergy Immunotherapy Market is expanding due to the increasing frequency of allergic illnesses such as allergic rhinitis, asthma, and food allergies. As more people seek effective, long-term treatment alternatives, the preference for immunotherapy over standard drugs is becoming clear. This is especially true for people who want to relieve their symptoms without having to use antihistamines or corticosteroids all the time.

Furthermore, advances in allergen-specific immunotherapy products and administration modalities such as sublingual tablets and injections, are improving patient access and adherence. Increasing awareness of immunotherapy's benefits combined with recommendations from healthcare experts is driving market expansion. With an emphasis on personalized medication, the allergy immunotherapy industry is expected to grow significantly in the coming years.

Allergy Immunotherapy Market: Definition/ Overview

Allergy immunotherapy is a treatment that aims to lower sensitivity to allergens resulting in long-term relief from allergy symptoms. It entails gradually administering increasing doses of certain allergens, either via subcutaneous injections (allergen immunotherapy) or sublingual tablets/drops. This mechanism helps the immune system develop tolerance to allergens reducing the severity of allergic reactions.

It is used to treat allergy diseases by progressively reducing the immune system's sensitivity to specific allergens. It entails the introduction of allergens in controlled dosages by injections (subcutaneous immunotherapy) or sublingual pills. This approach reduces the severity of allergic reactions over time and can provide long-term relief, even after therapy is completed. Allergy immunotherapy is beneficial for illnesses such as allergic rhinitis, asthma, and specific food allergies enhancing patients' quality of life and lowering drug use.

The future of allergy immunotherapy will center on personalized treatment techniques that use genetic and biomarker data to adapt medicines to specific patients. Innovative drug delivery systems, such as microneedles and wearable devices are expected to improve patient compliance and comfort. Furthermore, studies on new allergen sources and combination medicines will expand therapy choices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How has the Rising Awareness among Healthcare Professionals and Patients Impacted the Growth of the Allergy Immunotherapy Market?

Rising awareness among healthcare professionals and patients has accelerated the growth of the Allergy Immunotherapy Market. As more healthcare practitioners recognize the long-term benefits of immunotherapy over traditional allergy medications, they are more likely to promote it as a viable allergy management option. This shift in clinical practice, fuelled by improved education on the efficacy and safety of immunotherapy has resulted in increased acceptance of therapies such as Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), hence contributing to market growth.

From the patient's perspective, a rising understanding of allergy immunotherapy's ability to provide long-term comfort, rather than just temporary symptom relief has resulted in increased demand for these therapies. As patients become more aware of their alternatives, they are more likely to choose personalized, long-term allergy treatments. This rising demand combined with professional endorsements from healthcare practitioners has pushed the adoption of immunotherapy propelling total market expansion.

How Does the High Cost of Treatment Act as a Restraint in the Allergy Immunotherapy Market?

The high cost of treatment is a significant barrier in the Allergy Immunotherapy Market limiting patient access to care. Allergy immunotherapy, particularly Subcutaneous Immunotherapy (SCIT) needs several sessions over several years which can be costly for patients. In many areas, insurance coverage for such therapies may be limited or absent requiring patients to pay out of cash. Even though the therapy provides long-term relief for chronic allergy problems, many people are put off by the cost.

Furthermore, the high initial and recurring costs associated with immunotherapy limit its accessibility, particularly in low-income regions or nations with inadequate healthcare resources. Allocating resources for extensive immunotherapy programs may be impractical for healthcare systems with limited finances, further restricting market expansion. As a result, despite the increasing incidence of allergies and the established efficacy of immunotherapy, cost remains a significant barrier to the wider use of these treatments.

Category-Wise Acumens

How Does the Method of Allergen Exposure in SCIT Contribute to the Long-Term Efficacy of Treatment for Allergic Diseases?

Subcutaneous Immunotherapy (SCIT) dominates the Allergy Immunotherapy Market due to its long-standing efficacy and comprehensive strategy. SCIT includes injecting allergen extracts directly under the skin allowing for controlled exposure and eventual desensitization of the immune system to specific allergens. This approach has been widely researched and shown helpful for a variety of allergens, notably pollen, dust mites, and animal dander making it a popular choice among both patients and healthcare providers looking for long-term relief.

Furthermore, SCIT provides a well-defined treatment regimen with established protocols resulting in predictable dose and response. The inclusion of multiple allergens in SCIT formulations allows for more personalized therapy options for patients which improves compliance and satisfaction. While sublingual immunotherapy (SLIT) is gaining popularity due to its simplicity of administration, SCIT remains dominant due to its proven track record, strong clinical data, and allergists' preference for its comprehensive approach to addressing allergic diseases.

How Does the Preparation of Personalized Immunotherapy Regimens in Hospital Pharmacies Affect Patient Adherence to Treatment Plans?

Hospital pharmacies dominate the allergy immunotherapy industry because they have access to a wide choice of specialized drugs and treatment alternatives. These pharmacies are ready to prepare and distribute personalized immunotherapy regimens such as allergy injections and sublingual pills, based on patient needs. The presence of allergists and immunologists in hospital settings promotes teamwork, resulting in better patient care and monitoring throughout the therapy process. This integrated strategy guarantees that patients receive timely and effective medicines which leads to better outcomes.

Furthermore, hospital pharmacies benefit from established partnerships with pharmaceutical producers allowing them to obtain the most recent immunotherapy medicines and updates on treatment methods. As hospitals implement multidisciplinary care models, coordination among chemists, healthcare professionals, and patients improves. This comprehensive strategy not only improves patient adherence to medication but also creates a supportive atmosphere for continued education and follow-up reinforcing hospital pharmacies' role in the Allergy Immunotherapy Market.

Country/Region-wise Acumens

How do Reimbursement Policies Influence Patient Access to Allergy Immunotherapy in the North American Region?

North America dominates the Allergy Immunotherapy Market, owing to the increasing prevalence of allergic illnesses like allergic rhinitis and asthma which drives demand for better treatment alternatives. The region benefits from excellent healthcare facilities, extensive research programs, and a thriving pharmaceutical sector. Major corporations are significantly investing in novel medicines such as subcutaneous and sublingual immunotherapy, to meet the rising patient population. Furthermore, as healthcare practitioners and patients become more aware of allergic disorders, acceptance and usage of immunotherapy treatments have increased.

Furthermore, supporting regulatory frameworks and favorable reimbursement policies in the United States promote market expansion. The Food and Drug Administration (FDA) has approved several immunotherapy medicines, increasing their market penetration. North American healthcare systems prioritize personalized medicine and patient-centered approaches which encourages the use of allergy immunotherapy. As a result, the region is well-positioned to sustain its market leadership opening the path for ongoing breakthroughs in treatment techniques.

How are Changing Lifestyles and Urbanization Impacting the Prevalence of Asthma and Allergic Rhinitis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the Allergy Immunotherapy Market owing to rising allergy incidence, increased healthcare awareness, and considerable investment in R&D. Urbanisation and changing lifestyles have contributed to an increase in allergy disorders such as asthma and allergic rhinitis creating a larger demand for effective treatments. As more people become aware of the benefits of immunotherapy, healthcare providers are more likely to recommend it resulting in increased market growth.

Furthermore, supportive government initiatives and partnerships with pharmaceutical companies improve access to allergy treatments and advances. The region's increasing middle class is pushing up healthcare spending allowing for the adoption of modern therapeutic choices. Furthermore, the expansion of healthcare infrastructure and the growing number of allergists and immunologists in countries such as China and India are key drivers of market growth. Overall, the combination of increased allergies and greater healthcare access has positioned Asia Pacific as a market leader in allergy immunotherapy.

Competitive Landscape

The Allergy Immunotherapy Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Allergy Immunotherapy Market include:

ALK-Abello A/S, Stallergenes Greer plc, Allergy Therapeutics plc, Merck & Co., Inc. (known as MSD outside of the United States and Canada), Aimmune Therapeutics, Inc., DBV Technologies SA, HAL Allergy Group, Biomay AG, Circassia Pharmaceuticals plc, Immunomic Therapeutics, Inc., Anergis, ASIT Biotech, and Adamis Pharmaceuticals Corporation.

Latest Developments

In January 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), two clinical-stage immunotherapeutic companies, announced a collaboration to develop a novel oral mucosal allergy immunotherapy for treating peanut allergy.

In October 2023, ALK reported the successful completion of Itulatek's phase 3 trial for treating allergy rhinoconjunctivitis caused by tree pollen.

1 INTRODUCTION OF GLOBAL ALLERGY IMMUNOTHERAPY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ALLERGY IMMUNOTHERAPY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY ALLERGEN TYPE

5.1 Overview
5.2 Seasonal Allergens
5.3 Perennial Allergens

6 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY AGE GROUP

6.1 Overview
6.2 Children
6.3 Adults

7 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY TYPE OF IMMUNOTHERAPY

7.1 Overview
7.2 Subcutaneous Immunotherapy (SCIT)
7.3 Sublingual Immunotherapy (SLIT)

8 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

8.1 Hospital Pharmacies
8.2 Retail Pharmacies
8.3 Online Pharmacies

9 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East & Africa

10 GLOBAL ALLERGY IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 ALK-Abello A/S
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Stallergenes Greer plc
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Allergy Therapeutics plc
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Aimmune Therapeutics, Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 DBV Technologies SA
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 HAL Allergy Group
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Biomay AG
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Circassia Pharmaceuticals plc
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Immunomic Therapeutics, Inc.
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Anergis
- 11.11.1 Overview
- 11.11.2 Financial Performance
- 11.11.3 Product Outlook
- 11.11.4 Key Developments